MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.24
-0.09
-0.22%
Closed 16:01 05/07 EDT
OPEN
41.43
PREV CLOSE
40.33
HIGH
41.74
LOW
40.18
VOLUME
636.47K
TURNOVER
--
52 WEEK HIGH
70.82
52 WEEK LOW
38.01
MARKET CAP
2.84B
P/E (TTM)
-5.9820
1D
5D
1M
3M
1Y
5Y
Cystic Fibrosis Market 2021: Latest Industry Size, Growth, Share, Demand, Trends, Competitive Landscape and Forecasts to 2023 with Top Countries Data
May 07, 2021 (AmericaNewsHour) -- The major factors responsible for the growth of global cystic fibrosis market are; development of new drugs and therapies,...
AmericaNewsHour · 1d ago
Global Phenylketonuria Drugs Market to Grow with a Significant CAGR Throughout 2021-2029; Rising Prevalence of Phenylketonuria Disorder Globally to Drive Market Growth
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Phenylketonuria Drugs market- Global Demand Analysis and Opportunity Outlook...
AmericaNewsHour · 1d ago
Cystic Fibrosis Market 2021: Top Countries Data with Market Size, Comprehensive Research Methodology, Regional Study and Business Operation Data Analysis by 2023
May 07, 2021 (AmericaNewsHour) -- Cystic fibrosis is a chronic, genetic disease which affects the productivity of the body leading to severe disability and...
AmericaNewsHour · 2d ago
DJ PTC Therapeutics, Inc. CEO Stuart Peltz on Q1 2021 Results -- Earnings Call Transcript >PTCT
Dow Jones · 2d ago
Albireo Reports Q1 Financial Results and Business Update
BOSTON, May 06, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- - BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and...
GlobeNewswire · 2d ago
31.8% Return Seen to Date on SmarTrend Ptc Therapeutics Call (PTCT)
May 06, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Ptc Therapeutics (NASDAQ:PTCT) on February 17th, 2021 at $59.94. In...
marketwatch.com · 3d ago
PTC Therapeutics Stock Appears To Be Modestly Undervalued
GuruFocus News · 3d ago
--RBC Capital Adjusts PTC Therapeutics' Price Target to $48 From $49, Keeps Sector Perform Rating
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTCT. Analyze the recent business situations of PTC Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTCT stock price target is 58.33 with a high estimate of 75.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 320
Institutional Holdings: 75.15M
% Owned: 106.66%
Shares Outstanding: 70.46M
TypeInstitutionsShares
Increased
66
3.31M
New
38
767.99K
Decreased
82
2.41M
Sold Out
21
178.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Michael Schmertzler
Chief Executive Officer/Director
Stuart Peltz
Chief Financial Officer/Treasurer
Emily Hill
Chief Operating Officer
Marcio Souza
Executive Vice President
Mark Boulding
Senior Vice President - Finance/Chief Accounting Officer
Christine Utter
Other
Neil Almstead
Other
Matthew Klein
Other
Eric Pauwels
Independent Director
Allan Jacobson
Independent Director
Stephanie Okey
Independent Director
Emma Reeve
Independent Director
David Southwell
Independent Director
Glenn Steele
Independent Director
Dawn Svoronos
Independent Director
Jerome Zeldis
No Data
  • All
  • Financials
  • Insiders
More
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and PTC923 for phenylketonuria (PKU) diseases.

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.